Davion Healthcare Plc (NASDAQ: DAVI) announced that its ordinary shares are expected to commence trading on the Nasdaq Global Market on Thursday, October 22, 2026. The listing marks a significant milestone for the digital healthcare company as it advances the commercialisation of its proprietary non-invasive monitoring technologies.

The company simultaneously unveiled a new executive leadership structure effective upon the start of trading. Glenn Williams has been appointed Chief Executive Officer, while Jeremy North will serve as Chief Operating Officer. Jack Kaye, the current Chief Executive Officer, will transition to the role of Chairman, providing strategic guidance to the Board.

Strategic focus on commercialisation and acquisitions

Davion’s growth strategy integrates the commercialisation of its core technologies with the acquisition of complementary healthcare businesses. The Group recently established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond to fund this acquisition programme. The capital is intended to support investments in medical devices, healthcare services, distribution networks, and diagnostics.

The company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through temperature changes. The test is completed in under 15 minutes, with results delivered via a mobile app or online platform. Davion emphasises that BreastCheck supports proactive monitoring but does not replace mammography or clinical diagnosis.

Leadership and operational structure

To support its expansion, Davion is establishing an Operational Directorate as its principal executive management body. Led by CEO Glenn Williams, the Directorate includes the Chief Financial Officer, Chief Operating Officer, and Chief Commercial Officer. This structure separates day-to-day execution from Board oversight, which retains responsibility for overall strategy, governance, and major capital allocation decisions.

Glenn Williams brings extensive experience in healthcare systems and private equity-backed businesses, having participated in transactions valued at over $350 million. Jeremy North adds expertise in corporate finance and public markets, with prior experience leading the turnaround and sale of CloudMade Group to Stellantis.

Portfolio expansion beyond breast health

While BreastCheck anchors the consumer health portfolio, Davion is developing additional proprietary technologies aimed at preventive care outside traditional clinical settings. The broader pipeline includes:

• FootFlow: Monitors circulation and diabetes-related blood flow indicators.
• Testic: An at-home testicular health monitoring system.
• ThermaDerm: Identifies skin anomalies.
• Other Technologies: Addressing wound monitoring, blood pressure, and general preventive healthcare.

Maxim Group LLC served as the financial advisor for the Nasdaq listing. The move to list during Breast Cancer Awareness Month underscores the company’s focus on early detection technologies.

Davion Healthcare Plc has entered into a share purchase agreement to acquire 100% of Humaskan Ltd for a total consideration of $60m. The transaction is intended to expand Davion's healthcare platform by adding proprietary healthcare products and intellectual property. Concurrently, the company announced the proposed establishment of a wholly owned United Kingdom subsidiary, Davion Healthcare Finance Ltd, to support its planned acquisition and expansion strategy across the United States and Europe.

The consideration for the Humaskan acquisition comprises $10m in cash and $50m through the issue of ordinary shares in Davion. The equity consideration is proposed to be issued at a reference price of $13.00 per share. This issuance is subject to a nine-month lock-up arrangement, followed by orderly market disposal provisions. The acquisition follows the recently announced purchase of Solar Medical and Chemical Limited, which is intended to establish Davion's principal commercial and distribution platform in the United Kingdom.

To fund its acquisition programme, Davion intends to establish a corporate bond programme of up to £100m through Davion Healthcare Finance Ltd. The proposed programme is expected to comprise three series: Series 1 of up to £30m, Series 2 of up to £30m, and Series 3 of up to £40m. The bonds are expected to carry an indicative fixed coupon of 10.5% per annum with a maturity profile of five years. The offering will be exclusive to professional, sophisticated, and institutional investors.

Subject to final approvals and market conditions, Davion anticipates that each bond series will apply for admission to trading on the Vienna Stock Exchange MTF platform. Launch activities are currently anticipated to commence in August 2026. Proceeds from the programme will be directed toward the Group's acquisition activities in Europe and the United States. The bond programme is intended to be structured with Davion Healthcare Finance Ltd as the issuer, with acquisition assets subject to dedicated security arrangements.

Transaction and Financing Details

The following table outlines the key financial metrics for the proposed acquisition and financing initiative:

Strategic Rationale

The Board believes the combined strategy of acquiring Humaskan and establishing the financing subsidiary will accelerate Davion's broader healthcare platform strategy. The move is intended to broaden the company's healthcare technology portfolio, expand product development and manufacturing capabilities, and create additional routes for revenue growth. Jack Kaye, CEO of Davion Healthcare Plc, stated that combining proprietary technologies with access to long-term institutional capital creates a flexible foundation for future growth. Completion of the transaction and implementation of the financing programme remain subject to definitive documentation, regulatory considerations, and satisfaction of customary conditions.